On September 30, 2025, Entero Therapeutics, Inc. completed a Share Exchange Agreement with GridAI Corp, acquiring 424,348 shares (19.99% of common stock) and 38,801,546 preferred shares convertible into common stock, supporting Nasdaq compliance with at least $2.5 million in equity.